Literature DB >> 27490409

Impact of Immune-Modulatory Drugs on Regulatory T Cell.

Akiko Furukawa1, Steven A Wisel1, Qizhi Tang1.   

Abstract

Immunosuppression strategies that selectively inhibit effector T cells while preserving and even enhancing CD4FOXP3 regulatory T cells (Treg) permit immune self-regulation and may allow minimization of immunosuppression and associated toxicities. Many immunosuppressive drugs were developed before the identity and function of Treg were appreciated. A good understanding of the interactions between Treg and immunosuppressive agents will be valuable to the effective design of more tolerable immunosuppression regimens. This review will discuss preclinical and clinical evidence regarding the influence of current and emerging immunosuppressive drugs on Treg homeostasis, stability, and function as a guideline for the selection and development of Treg-friendly immunosuppressive regimens.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27490409      PMCID： PMC5077666          DOI： 10.1097/TP.0000000000001379

Source DB:  PubMed          Journal:  Transplantation        ISSN： 0041-1337            Impact factor:   4.939


  249 in total

Review 1.  Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty.

Authors:  W B Ershler; E T Keller
Journal:  Annu Rev Med       Date:  2000       Impact factor: 13.739

2.  Regulatory T cells in kidney transplant recipients: the effect of induction immunosuppression therapy.

Authors:  Eva Krystufkova; Alena Sekerkova; Ilja Striz; Irena Brabcova; Eva Girmanova; Ondrej Viklicky
Journal:  Nephrol Dial Transplant       Date:  2011-12-13       Impact factor: 5.992

3.  Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A.

Authors:  Thomas Giese; Martin Zeier; Peter Schemmer; Waldemar Uhl; Margarita Schoels; Thomas Dengler; Markus Buechler; Stefan Meuer
Journal:  Transplantation       Date:  2004-02-15       Impact factor: 4.939

4.  CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells.

Authors:  Tomoko Watanabe; Jun-ichi Masuyama; Yoshiaki Sohma; Hiroko Inazawa; Kaori Horie; Kumiko Kojima; Yasunori Uemura; Yumi Aoki; Shuji Kaga; Seiji Minota; Toshiyuki Tanaka; Yasunori Yamaguchi; Tetsuto Kobayashi; Isao Serizawa
Journal:  Clin Immunol       Date:  2006-06-22       Impact factor: 3.969

5.  Immune regulation by CD52-expressing CD4 T cells.

Authors:  Ban-Hock Toh; Tin Kyaw; Peter Tipping; Alex Bobik
Journal:  Cell Mol Immunol       Date:  2013-08-12       Impact factor: 11.530

Review 6.  Rabbit antithymocyte globulin (thymoglobulin): 25 years and new frontiers in solid organ transplantation and haematology.

Authors:  A Osama Gaber; Anthony P Monaco; James A Russell; Yvon Lebranchu; Mohamad Mohty
Journal:  Drugs       Date:  2010-04-16       Impact factor: 9.546

7.  CTLA4Ig inhibits effector T cells through regulatory T cells and TGF-β.

Authors:  Christine M Deppong; Traci L Bricker; Brandy D Rannals; Nico Van Rooijen; Chyi-Song Hsieh; Jonathan M Green
Journal:  J Immunol       Date:  2013-08-16       Impact factor: 5.422

8.  Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity.

Authors:  Keli L Hippen; Sarah C Merkel; Dawn K Schirm; Christine M Sieben; Darin Sumstad; Diane M Kadidlo; David H McKenna; Jonathan S Bromberg; Bruce L Levine; James L Riley; Carl H June; Phillip Scheinberg; Daniel C Douek; Jeffrey S Miller; John E Wagner; Bruce R Blazar
Journal:  Sci Transl Med       Date:  2011-05-18       Impact factor: 17.956

9.  Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.

Authors:  Xin Zhang; Yazhong Tao; Manisha Chopra; Mihye Ahn; Karen L Marcus; Neelima Choudhary; Hongtu Zhu; Silva Markovic-Plese
Journal:  J Immunol       Date:  2013-11-06       Impact factor: 5.422

10.  Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates.

Authors:  Tim A Weaver; Ali H Charafeddine; Avinash Agarwal; Alexandra P Turner; Maria Russell; Frank V Leopardi; Robert L Kampen; Linda Stempora; Mingqing Song; Christian P Larsen; Allan D Kirk
Journal:  Nat Med       Date:  2009-07-05       Impact factor: 53.440
View more
  39 in total

Review 1.  Stem Cell Therapies for Treating Diabetes: Progress and Remaining Challenges.

Authors:  Julie B Sneddon; Qizhi Tang; Peter Stock; Jeffrey A Bluestone; Shuvo Roy; Tejal Desai; Matthias Hebrok
Journal:  Cell Stem Cell       Date:  2018-06-01       Impact factor: 24.633

Review 2.  Transplant trials with Tregs: perils and promises.

Authors:  Qizhi Tang; Flavio Vincenti
Journal:  J Clin Invest       Date:  2017-06-30       Impact factor: 14.808

3.  Regulatory T Cells for the Induction of Transplantation Tolerance.

Authors:  Weitao Que; Xiao-Kang Li
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  The Pursuit of Regulatory T Cells in the Induction of Transplant Tolerance.

Authors:  Preston R Arnold; Xian C Li
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Distinct peripheral blood molecular signature emerges with successful tacrolimus withdrawal in kidney transplant recipients.

Authors:  Paolo Cravedi; Miguel Fribourg; Weijia Zhang; Zhengzi Yi; Elena Zaslavsky; German Nudelman; Lisa Anderson; Susan Hartzell; Sophie Brouard; Peter S Heeger
Journal:  Am J Transplant       Date:  2020-05-27       Impact factor: 8.086

6.  Comparative study of human and cynomolgus T-cell depletion with rabbit anti-thymocyte globulin (rATG) treatment-for dose adjustment in a non-human primate kidney transplantation model.

Authors:  Yeongbeen Kwon; Kyo Won Lee; Hyojun Park; Jin Kyung Son; JongHyun Lee; Juhee Hong; Jae Berm Park; Sung Joo Kim
Journal:  Am J Transl Res       Date:  2019-10-15       Impact factor: 4.060

7.  Combined OX40L and mTOR blockade controls effector T cell activation while preserving Treg reconstitution after transplant.

Authors:  Victor Tkachev; Scott N Furlan; Benjamin Watkins; Daniel J Hunt; Hengqi Betty Zheng; Angela Panoskaltsis-Mortari; Kayla Betz; Melanie Brown; John B Schell; Katie Zeleski; Alison Yu; Ian Kirby; Sarah Cooley; Jeffrey S Miller; Bruce R Blazar; Duncan Casson; Phil Bland-Ward; Leslie S Kean
Journal:  Sci Transl Med       Date:  2017-09-20       Impact factor: 17.956

Review 8.  Next-generation regulatory T cell therapy.

Authors:  Leonardo M R Ferreira; Yannick D Muller; Jeffrey A Bluestone; Qizhi Tang
Journal:  Nat Rev Drug Discov       Date:  2019-09-20       Impact factor: 84.694

Review 9.  Exploring the Pathogenic Role and Therapeutic Implications of Interleukin 2 in Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2020-08-24       Impact factor: 3.199

Review 10.  Natural killer cells in lung transplantation.

Authors:  Daniel R Calabrese; Lewis L Lanier; John R Greenland
Journal:  Thorax       Date:  2018-10-31       Impact factor: 9.139
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.